Order online or whatsapp us +1‪(512) 387-0557‬


ACE-031 Peptide


ACE-031 Peptide

Product Name: ACE-031
Appearance: Lyophilized White Powder
Purity: Above 98.00% +
Specification: 10mg/vial
Standard: Pharmaceutical Grade
Application Type: For Injection Usage
Storage: Store Lyophilized Protein at -20 °C
Stability: 2-3 Years
Supplying Form: Freeze-Dried Powder in Vial
Min Order: 10 vial


Share this product

Raw Novel Muscle-building Agent ACE-031,85% ACE-031 White Powder

ACE-031 Peptide Detaills:
Ace-031 Specification: 1mg/vial, 2mg/vial
Ace-031 Appearance: White Lyophilized Powder
Ace-031 Half life: 10-15 days
Ace-031 Storage: Below -18c
Ace-031 Usage: Myostatin Inhibitor, Bodybuilding
Ace-031 Solubility: Soluble in water or 1% acetic acid
Ace-031 Purity:85%

ACE-031 Peptide Description:
ACE-031 (Neuromuscular Disease) ACE-031 is a novel, muscle-building agent that is being developed for the treatment of patients with Duchenne Muscular Dystrophy with the goal of improving strength and preserving physical function. Ace-031 peptide was genetically developed to bind to myostatin before it can attach to its receptor and halt muscle growth.
ACE-031 Peptide Usage:
In the different studies that were conducted, subjects experienced a reduction in leptin concentration and boosted adiponectin, Ace-031 is a ‘good fat’ hormone.  Hence, perhaps Ace-031 does really contribute to fat loss.  Another study showed an increase in alkaline phosphatase in the blood and reduced collagen telopeptide; this may mean it also helps strengthening the bones.

ACE-031 Peptide Dosage:
Even a small dose of ACE-031 of 1 mg can have a substantial effect. Sportsmen taking 1 mg of ACE-031 once a week over the period of 3-4 weeks report nearly an immediate increase in the muscle hardness and the rapid growth of muscle mass and strength to an extent exceeding even the most efficient hardcore volume anabolic-androgenic steroid, such as Oxymetholone!


There are no reviews yet.

Be the first to review “ACE-031 Peptide”

Your email address will not be published. Required fields are marked *